By SPC News Staff
The FDA approved glecaprevir-pibrentasvir (Mavyret, AbbVie) to treat adults with chronic hepatitis C virus (HCV) genotypes 1 to 6 without cirrhosis or with mild cirrhosis, including patients with moderate to severe renal disease and those who are on dialysis.
Glecaprevir-pibrentasvir is also approved for adults with HCV genotype 1 infection who have been treated with a regimen either containing a nonstructural protein 5A (NS5A) inhibitor or an NS3/4A protease inhibitor, but not